GTA VI Launch Unlocks Nov 19 at midnight local time: 00h 00m 00s Launch Guide →

Isomorphic Labs Raises $5 Billion: What Its AI Drug Discovery Strategy Means

The Alphabet spinout led by Sir Demis Hassabis doubled down on its May funding with a record TechBio round aimed at transforming pharmaceutical R&D.

OB
Olivia Bennett
Senior Business Editor
• 2 min read
Pinterest aesthetic photography of clean modern biotechnology research laboratory
Pinterest aesthetic photography of clean modern biotechnology research laboratory

Isomorphic Labs, the Alphabet and DeepMind spinout led by Sir Demis Hassabis, raised $5 billion in a Series C financing announced on November 17, 2026, setting a new venture capital record for the biotech and TechBio sector. The round was co-led by Greenoaks and Sequoia Capital alongside Andreessen Horowitz and Alphabet, with additional backing from Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. The raise more than doubles the $2.1 billion Series B the company closed just six months earlier in May 2026.

Scaling IsoDDE from algorithms to clinical candidates

The fresh capital is earmarked to scale the company's IsoDDE drug design engine and expand its internal therapeutic pipeline across oncology and immunology. Traditional pharmaceutical discovery routinely consumes more than a decade and billions of dollars per approved therapy, largely because most candidate molecules fail during preclinical screening or human trials. Isomorphic Labs aims to compress early discovery timelines and improve hit rates by predicting protein interactions, molecular binding affinities, and chemical properties in silico before wet-lab synthesis begins.

Building a defensible scientific model at that level demands enormous compute power alongside wet-lab validation infrastructure and seasoned medicinal chemists. Raising $5 billion in a single tranche insulates the company from public biotech market swings while funding multiple parallel drug programs rather than betting its survival on one compound.

Why top Silicon Valley investors are backing TechBio

The investor syndicate signals an important shift in venture strategy. As enterprise chatbots and horizontal coding tools grow crowded, blue-chip funds are allocating massive pools of capital toward AI applications anchored in physical-world intellectual property. A successful oncology or immunology drug carries patent-protected cash flows that software competitors cannot easily clone.

Still, computational breakthroughs cannot bypass biology or regulators. Human clinical trials remain slow, costly, and unforgiving. Over the next several years, Isomorphic Labs will be judged not by model benchmarks or funding records, but by whether its AI-designed molecules clear Phase I and Phase II clinical milestones.

Isomorphic Labs $5 billion Isomorphic Labs Series C Demis Hassabis AI biotech IsoDDE drug design AI drug discovery 2026

More from Bugwrite